Literature DB >> 9537805

Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.

A Pinelli1, S Trivulzio, L Tomasoni.   

Abstract

This study tested whether a 5-HT3 receptor antagonist could reverse the signs of precipitated opioid withdrawal. Rats were treated with either saline or morphine for 4 days. After the four days, half of the rats in each group received naloxone and half received saline. Each animal also received one of four doses of ondansetron (0, 1, 2 and 4 mg/kg i.p.). Administration of ondansetron to rats receiving naloxone after chronic morphine decreased the intensity of withdrawal signs such as increased defecation, jumping and wet-dog shakes, elevated the nociceptive threshold values which were decreased by precipitated withdrawal, but produced no change in urination, rectal temperature or salivation. The effects exhibited by ondansetron administration may be explained through interference of its 5-HT3 receptor antagonist activity with serotoninergic mechanisms involved in the regulation of these withdrawal symptoms. The use of this drug is thus suggested as a possible treatment of opioid withdrawal signs in heroin addicts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9537805     DOI: 10.1016/s0014-2999(97)01349-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Effects of repeated morphine on ultrasonic vocalizations in adult rats: increased 50-kHz call rate and altered subtype profile.

Authors:  Laura M Best; Leah L Zhao; Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2016-10-11       Impact factor: 4.530

2.  Descending facilitatory pathways from the rostroventromedial medulla mediate naloxone-precipitated withdrawal in morphine-dependent rats.

Authors:  Louis P Vera-Portocarrero; Michael H Ossipov; Josephine Lai; Tamara King; Frank Porreca
Journal:  J Pain       Date:  2011-02-26       Impact factor: 5.820

Review 3.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

Review 4.  Ondansetron does not reduce the shivering threshold in healthy volunteers.

Authors:  R Komatsu; M Orhan-Sungur; J In; T Podranski; T Bouillon; R Lauber; S Rohrbach; D Sessler
Journal:  Br J Anaesth       Date:  2006-05-04       Impact factor: 9.166

5.  Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.

Authors:  Matthew J Erlendson; Nicole D'Arcy; Ellen M Encisco; Jeffrey J Yu; Lorena Rincon-Cruz; Gary Peltz; J David Clark; Larry F Chu
Journal:  Am J Drug Alcohol Abuse       Date:  2016-08-11       Impact factor: 3.829

6.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

Review 7.  Molecular basis of alcoholism.

Authors:  Dana Most; Laura Ferguson; R Adron Harris
Journal:  Handb Clin Neurol       Date:  2014

8.  Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.

Authors:  Lisa L Wilson; Soumen Chakraborty; Shainnel O Eans; Thomas J Cirino; Heather M Stacy; Chloe A Simons; Rajendra Uprety; Susruta Majumdar; Jay P McLaughlin
Journal:  Cell Mol Neurobiol       Date:  2021-01-12       Impact factor: 4.231

9.  Alleviating symptoms of withdrawal from an opioid.

Authors:  Judith H Wakim
Journal:  Pain Ther       Date:  2012-09-20

10.  NEURONAL CORRELATES OF HYPERALGESIA AND SOMATIC SIGNS OF HEROIN WITHDRAWAL IN MALE AND FEMALE MICE.

Authors:  Yocasta Alvarez-Bagnarol; Renata C N Marchette; Chase Francis; Marisela M Morales; Leandro F Vendruscolo
Journal:  eNeuro       Date:  2022-06-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.